Prospective, Open-label, Multi-centre Phase 3b Study to Assess the Efficacy and Safety of Personalized Prophylaxis With Human-cl rhFVIII in Previously Treated Adult Patients With Severe Haemophilia A
Phase of Trial: Phase III
Latest Information Update: 16 Aug 2017
At a glance
- Drugs Simoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Sponsors Octapharma
- 28 Jun 2017 Planned End Date changed from 1 Apr 2018 to 1 Dec 2019.
- 28 Jun 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Sep 2018.
- 19 Apr 2017 Snapshot results presented at the Hemostasis and Thrombosis Research Society Scientific Symposium 2017, according to an Octapharma USA media release.